Guidelines for cytogenetic investigations in tumours

European Journal of Human Genetics

Volumn 24, Issue 1, 2016, Pages 6-13

  Hastings, Rosalind J ^a   Bown, Nick ^b   Tibiletti, Maria G ^c   Debiec Rychter, Maria ^d   Vanni, Roberta ^e   Espinet, Blanca ^f   Van Roy, Nadine ^g   Roberts, Paul ^h   Van Den Berg De Ruiter, Eva ⁱ   Bernheim, Alain ^j   Schoumans, Jacqueline ^k   Chatters, Steve ^l   Zemanova, Zuzana ^m   Stevens Kroef, Marian ⁿ   Simons, Annet ⁿ   Heim, Sverre ^o   Salido, Marta ^f   Ylstra, Bauke ^p   Betts, David R ^q  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f HOSPITAL DEL MAR   (Spain)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j INSERM   (France)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o OSLO UNIVERSITY HOSPITAL   (Norway)

^p University of Amsterdam   (Netherlands)

^q OUR LADY S CHILDREN S HOSPITAL   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FORMALDEHYDE; BIOLOGICAL MARKER; PARAFFIN; TUMOR PROTEIN;

BONE MARROW BIOPSY; CELL STRUCTURE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME BANDING PATTERN; CYTOGENETICS; CYTOLOGY; CYTOSPIN; DIFFERENTIAL DIAGNOSIS; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE SEQUENCE; HUMAN; MICROARRAY ANALYSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEOPLASM; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SANGER SEQUENCING; SILVER ENHANCED IN SITU HYBRIDIZATION; TISSUE SECTION; ACCREDITATION; CHROMOSOME ANALYSIS; EUROPE; GENE EXPRESSION; GENETICS; HIGH THROUGHPUT SEQUENCING; LEGISLATION AND JURISPRUDENCE; METABOLISM; METHODOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; STANDARDS; TISSUE FIXATION; TISSUE MICROARRAY;

ACCREDITATION; BIOMARKERS; BIOPSY, FINE-NEEDLE; CYTOGENETIC ANALYSIS; EUROPE; GENE EXPRESSION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASMS; PARAFFIN EMBEDDING; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TISSUE FIXATION;

EID: 84951573394     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2015.35     Document Type: Review

References (26)

1. Heim S, Mitelman F (eds): Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 3rd edn. New York: Wiley-Blackwell
2. European Cytogenetic Guidelines: ECA Newsletter, January 2012. Available at. http://e-c-a.eu/files/downloads/E.C.A.-General-Guidelines-Version%202.0.pdf (last accessed 16 January 2015)
3. ISO 15189: 2012 Medical laboratories-Requirements for quality and competence
4. Claustres M, Koz?ich V, Dequeker E et al. on behalf of the ESHG Quality committee: Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) (2013). Eur J Hum Genet 2013; 22: 160-170
5. Shaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel: S Karger, 2013
6. European co-operation for accreditation: Available at. http://www.european-accreditation.org/ (last accessed 16 January 2015)
7. UK NEQAS Executive Office: Sheffield S10 2PB. Available at. http://www.ukneqas.org.uk/ (last accessed 16 January 2015)
8. Krijgsman O, Israeli D, Haan JC et al. CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes Cancer 2012; 51: 344-352
9. Sie D, Snijders PJ, Meijer GA et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) 2014; 37: 353-361
10. Tuononen K, Mäki-Nevala S, Sarhadi VK et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 2013; 52: 503-511
11. The Royal College of Pathologists: The Retention and Storage of Pathological Records and Archives. London: The Royal College of Pathologists, 2006
12. Peiró G, D Mayr DHillemanns P et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004; 17: 277-287
13. Van Loo P, Nilsen G, Nordgard SH et al. Analyzing cancer samples with SNP arrays. Methods Mol Biol 2012; 802: 57-72
14. Krijgsman O, Carvalho B, Meijer GA, Steenbergen RD, Ylstra B. Focal chromosomal copy number aberrations in cancer-Needles in a genome haystack. Biochim Biophys Acta 2014; 1843: 2698-2704
15. Krijgsman O, Israeli D, Van Essen HF et al. Detection limits of DNA copy number alterations in heterogeneous cell populations. Cell Oncol (Dordr) 2013; 36: 27-36
16. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015; 27: 15-26
17. De Vree PJ, De Wit E, Yilmaz M et al. Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat Biotechnol 2014; 32: 1019-1025
18. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14: 703-718
19. Scheinin I, Sie D, Bengtsson H et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014; 24: 2022-2032
20. Ding L, Wendl MC, McMichael JF, Raphael BJ. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 2014; 15: 556-570
21. Rigter T, Henneman L, Kristoffersson U et al. Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat 2013; 34: 1322-1328
22. Ulahannan D, Kovac MB, Mulholland PJ, Cazier J-B, Tomlinson I. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer 2013; 109: 827-835
23. Tripathy D, Harnden K, Kimberly Blackwell K, Robson M. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. BMC Med 2014; 12: 140 (http://www.biomedcentral.com/1741-7015/12/140/-ins1)
24. Ambros PF, Ambros IM, Brodeur GM et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009; 100: 1471-1482
25. Walker RA, Bartlett JM, Dowsett M, Ellis IO et al. HER2 testing in the UK. further update to recommendations. J Clin Pathol 2008; 61: 818-824
26. Wolff AC, Hammond MEH, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 3997-4014